60%+ returns in 2025: Here’s how AI-powered stock investing has changed the game
DUBLIN - Tudor Investment Corporation has disclosed a 2.93% stake in Avadel Pharmaceuticals Plc, according to a regulatory filing published Tuesday.
The investment firm reported holding 2,851,586 ordinary shares in the pharmaceutical company, representing approximately 2.93% of the total shares. The position includes 2,849,286 owned and controlled shares, along with a small number of derivatives.
The disclosure, made under Irish Takeover Panel rules, also revealed that Tudor holds a short position of 5,998 shares, equivalent to about 0.006% of Avadel's outstanding stock.
The filing detailed several recent transactions, including the sale of 182 ordinary shares at prices ranging from $18.55 to $18.59 per share on October 27, 2025.
Tudor's options portfolio related to Avadel includes various put and call options with strike prices between $10 and $20, with expiration dates in January and March 2026.
The disclosure was required under Rule 8.3 of the Irish Takeover Panel Act, which mandates that entities with interests of 1% or more in relevant securities must disclose their positions.
The information was provided in a Form 8.3 filing, which is typically required during takeover situations, though the document did not specify details about any potential acquisition involving Avadel Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.